scholarly journals P60.12 Baseline Tumor Immune Cell Infiltration and Activation can Predict Checkpoint Inhibitor Pneumonitis in Lung Cancer Patients

2021 ◽  
Vol 16 (3) ◽  
pp. S546
Author(s):  
J. Bracht ◽  
S. Viteri ◽  
A. Aguilar ◽  
J.J. Garcia ◽  
C. Huang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Immune Cell ◽  
Checkpoint Inhibitor ◽  
Cell Infiltration ◽  
Immune Cell Infiltration ◽  
Lung Cancer Patients

Glut10 is a Novel Immune Regulator Involved in Lung Cancer Immune Cell Infiltration and Predicts Worse Survival When Transcriptionally Down-Regulated

2021 ◽  
Author(s):  
Lijuan Jian ◽  
Min Zhang ◽  
Qi Wu ◽  
Xinping Min ◽  
Bowen Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Immune Cell ◽  
Cancer Prognosis ◽  
Expression Level ◽  
Cell Infiltration ◽  
Gene Marker ◽  
Immune Cell Infiltration ◽  
Lung Cancer Patients ◽  
Kaplan Meier ◽  
Immune Response To Cancer

Abstract Background: GLUT10 is encoded by SLC2A10 gene. Recent investigations have shown that GLUT10 is not only involved in glucose metabolism, but also involved in the body's immune response to cancer cells. However, the correlations between GLUT10 expression and prognosis, immune cells infiltrating of different cancers remain unclear.Methods: We Knocked down SLC2A10 and performed transcriptome sequencing to analyze the biological function of GLUT10. The SLC2A10 expression level was analyzed by the Oncomine databases and Tumor immune Estimation Resource (TIMER) site. We evaluated the prognostic potential of SLC2A10 in different cancers using the Kaplan-Meier plotter database and the PrognoScan online software. The correlations between SLC2A10 expression and immune infiltrates were analyzed by TIMER. In addition, correlations between SLC2A10 expression and gene marker sets of immune infiltrates were analyzed by TIMER and GEPIA.Results: Knocking down of SLC2A10 widely activated immune and inflammatory signaling. SLC2A10 was abnormally expressed in several tumors. The expression level of SLC2A10 was closely correlated with cancer prognosis. Low SLC2A10 expression was related to poorer prognosis and increased malignancy of lung cancer. Lung cancer patients with low expression of SLC2A10 have a much shorter median survival time than patients with high expression of SLC2A10. SLC2A10 expression is closely related to different types of immune cell infiltration, particularly with macrophages.Conclusions: By using various databases and analysis software, we found that GLUT10 is involved in tumor immunity and is expected to serve as a therapeutic target in the future. Down-regulation of SLC2A10 expression predicts poor prognosis of lung cancer. GLUT10 may be a new important immune regulating molecular thus worth further focusing.

scholarly journals SFTPA1 is a potential prognostic biomarker correlated with immune cell infiltration and response to immunotherapy in lung adenocarcinoma

2021 ◽  
Author(s):  
Lu Yuan ◽  
Xixi Wu ◽  
Longshan Zhang ◽  
Mi Yang ◽  
Xiaoqing Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
T Cells ◽  
Lung Adenocarcinoma ◽  
Expression Profile ◽  
Immune Cell ◽  
Cell Infiltration ◽  
Immune Cell Infiltration ◽  
Regulatory Pathways ◽  
Chronic Lung Diseases ◽  
Potential Biomarker

AbstractPulmonary surfactant protein A1 (SFTPA1) is a member of the C-type lectin subfamily that plays a critical role in maintaining lung tissue homeostasis and the innate immune response. SFTPA1 disruption can cause several acute or chronic lung diseases, including lung cancer. However, little research has been performed to associate SFTPA1 with immune cell infiltration and the response to immunotherapy in lung cancer. The findings of our study describe the SFTPA1 expression profile in multiple databases and was validated in BALB/c mice, human tumor tissues, and paired normal tissues using an immunohistochemistry assay. High SFTPA1 mRNA expression was associated with a favorable prognosis through a survival analysis in lung adenocarcinoma (LUAD) samples from TCGA. Further GeneOntology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses showed that SFTPA1 was involved in the toll-like receptor signaling pathway. An immune infiltration analysis clarified that high SFTPA1 expression was associated with an increased number of M1 macrophages, CD8+ T cells, memory activated CD4+ T cells, regulatory T cells, as well as a reduced number of M2 macrophages. Our clinical data suggest that SFTPA1 may serve as a biomarker for predicting a favorable response to immunotherapy for patients with LUAD. Collectively, our study extends the expression profile and potential regulatory pathways of SFTPA1 and may provide a potential biomarker for establishing novel preventive and therapeutic strategies for lung adenocarcinoma.

scholarly journals Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment

2018 ◽  
Vol Volume 10 ◽  
pp. 5537-5544 ◽  
Author(s):  
Stefan Diem ◽  
Mirjam Fässler ◽  
Omar Hasan Ali ◽  
Marco Siano ◽  
Rebekka Niederer ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Risk Score ◽  
Cell Lung Cancer ◽  
Checkpoint Inhibitor ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Inhibitor Treatment

scholarly journals Expression signature, prognosis value and immune characteristics of cathepsin F in non-small cell lung cancer identified by bioinformatics assessment

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Liyuan Song ◽  
Xianhui Wang ◽  
Wang Cheng ◽  
Yi Wu ◽  
Min Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Molecular Markers ◽  
Cancer Patients ◽  
Targeted Therapies ◽  
Poor Prognosis ◽  
Immune Cell ◽  
Clinicopathological Parameters ◽  
Cancer Specific Survival ◽  
Lung Cancer Patients ◽  
Favorable Prognosis

Abstract Background In recent years, immunotherapies and targeted therapies contribute to population-level improvement in NSCLC cancer-specific survival, however, the two novel therapeutic options have mainly benefit patients containing mutated driven genes. Thus, to explore other potential genes related with immunity or targeted therapies may provide novel options to improve survival of lung cancer patients without mutated driven genes. CTSF is unique in human cysteine proteinases. Presently, CTSF has been detected in several cell lines of lung cancer, but its role in progression and prognosis of lung cancer remains unclear. Methods CTSF expression and clinical datasets of lung cancer patients were obtained from GTEx, TIMER, CCLE, THPA, and TCGA, respectively. Association of CTSF expression with clinicopathological parameters and prognosis of lung cancer patients was analyzed using UALCAN and Kaplan–Meier Plotter, respectively. LinkedOmics were used to analyze correlation between CTSF and CTSF co-expressed genes. Protein–protein interaction and gene–gene interaction were analyzed using STRING and GeneMANIA, respectively. Association of CTSF with molecular markers of immune cells and immunomodulators was analyzed with Immunedeconv and TISIDB, respectively. Results CTSF expression was currently only available for patients with NSCLC. Compared to normal tissues, CTSF was downregulated in NSCLC samples and high expressed CTSF was correlated with favorable prognosis of NSCLC. Additionally, CTSF expression was correlated with that of immune cell molecular markers and immunomodulators both in LUAD and LUSC. Noticeably, high expression of CTSF-related CTLA-4 was found to be associated with better OS of LUAD patients. Increased expression of CTSF-related LAG-3 was related with poor prognosis of LUAD patients while there was no association between CTSF-related PD-1/PD-L1 and prognosis of LUAD patients. Moreover, increased expression of CTSF-related CD27 was related with poor prognosis of LUAD patients while favorable prognosis of LUSC patients. Conclusions CTSF might play an anti-tumor effect via regulating immune response of NSCLC.

Impact of Checkpoint Inhibitor Immunotherapy, Primarily Pembrolizumab, on Infection Risk in Patients With Advanced Lung Cancer: A Comparative Retrospective Cohort Study

2020 ◽  
Author(s):  
Alexandre E Malek ◽  
Melissa Khalil ◽  
Ray Hachem ◽  
Anne Marie Chaftari ◽  
Johny Fares ◽  
...  
Keyword(s):  
Risk Factors ◽  
Lung Cancer ◽  
Urinary Tract ◽  
Cancer Treatment ◽  
Cancer Patients ◽  
Checkpoint Inhibitor ◽  
Advanced Lung Cancer ◽  
Lung Cancer Patients ◽  
Independent Risk Factors ◽  
Tract Infections

Abstract Background Checkpoint inhibitor (CPI) immunotherapy has revolutionized cancer treatment. However, immune-related adverse events and the risk of infections are not well studied. To assess the infectious risk of CPIs, we evaluated the incidence of infections in lung cancer patients treated with CPIs plus conventional chemotherapy (CC) vs CC alone. Methods We performed a retrospective comparative study of patients with advanced non–small cell lung cancer who received CPIs combined with CC and those treated with CC alone at our institution during January 2016 to February 2019. We compared clinical characteristics, treatments, and outcomes including infection rate and mortality between the groups. Results We identified 123 patients for the CPI group and 147 patients for the control (CC) group. Eighteen patients (15%) in the CPI group and 33 patients (22%) in the control group developed infections (P = .1). Pneumonia was the most common infection encountered in both groups. Urinary tract infection was higher in the CC group (40%) than in the CPI group (9%) (P = .01). On multivariable analysis, chronic obstructive pulmonary disease (P = .024), prior use of corticosteroids (P = .021), and neutropenia (P < .001) were independent risk factors for infection and severe infection requiring hospital admission. Chronic kidney disease (P = .02), prior cancer treatment (P = .023), and neutropenia (P < .0001) were identified as independent risk factors for all-cause mortality. Conclusions Lung cancer patients treated with CPIs combined with CC have a comparable risk of infection to those treated with CC alone, although there is a trend towards fewer infections in those given CPIs, particularly when it comes to urinary tract infections.

Sign in / Sign up

Export Citation Format

Share Document